Form 4: Sangamo Therapeutics Director Receives Significant Equity Grants

Sangamo Therapeutics, Inc. Director H. Stewart Parker was granted 25,000 restricted stock units and options to purchase 50,000 shares of common stock, aligning his interests with shareholders.

Summary

• H. Stewart Parker, a Director of Sangamo Therapeutics, Inc. (SGMO), acquired 25,000 shares of common stock through a Restricted Stock Unit (RSU) grant on June 12, 2025.
• These RSU shares were granted at a price of $0 and will fully vest on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders, subject to continuous service.
• Mr. Parker also acquired options to buy 50,000 shares of common stock on June 12, 2025, with an exercise price of $0.503 per share.
• These stock options were granted at a price of $0 and are immediately exercisable, expiring on June 11, 2035.
• The shares underlying the options will vest in 12 successive equal monthly installments following the grant date, subject to continuous service.
• Following these transactions, Mr. Parker beneficially owns 112,600 shares of common stock and 50,000 stock options.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates alignment of director interests with shareholders through equity grants, which is a standard and generally favorable practice, but it is a routine disclosure rather than a significant strategic or financial announcement.

Positives

• The acquisition of additional equity by a director, H. Stewart Parker, through RSU and stock option grants, aligns his financial interests more closely with those of the company's shareholders.
• The grants are part of a standard equity incentive plan, indicating a structured approach to director compensation and retention.

Risks

• The vesting of both the restricted stock units and the stock options is subject to the Reporting Person's 'Continuous Service' as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, meaning the benefits are contingent on continued employment or board service.
• Any unvested shares purchased under the stock option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service.

Future Outlook

The equity grants include vesting schedules extending into 2026 and beyond, indicating a long-term commitment from the director to the company's performance and continued service.

Industry Context

The granting of restricted stock units and stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages designed to attract, retain, and incentivize leadership by aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• The structure of these equity grants, including vesting schedules tied to continuous service and an exercise price for options, is consistent with standard compensation practices for directors in publicly traded companies, particularly within the life sciences sector.
• While specific comparable companies or projects are not detailed in the filing, this type of equity compensation is a widely accepted mechanism for aligning director incentives with company performance, similar to practices observed at peers like CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT) for their board members.

Corporate Governance

Related Party Transactions

• The grants of restricted stock units and stock options to H. Stewart Parker, a Director of Sangamo Therapeutics, Inc., constitute related party transactions as they involve compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of the director's financial interests with long-term shareholder value.
• Employees: No direct impact mentioned, but the 2018 EIP may also apply to other employees, potentially indicating a broader incentive framework.
• Management: The grants incentivize the director to contribute to the company's success and retention.

Next Steps

• The 25,000 Restricted Stock Units are expected to fully vest on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders.
• The 50,000 stock options will vest in 12 successive equal monthly installments following the grant date, with the potential for exercise upon vesting.

Key Dates

Recommendation

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Trading, Equity Grant, Restricted Stock Unit, RSU, Stock Option, Director Compensation, Beneficial Ownership